H

Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627

Watchlist Manager
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Watchlist
Price: 4.26 CNY 0.95% Market Closed
Market Cap: 21B CNY
Have any thoughts about
Hubei Biocause Pharmaceutical Co Ltd?
Write Note

Hubei Biocause Pharmaceutical Co Ltd
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hubei Biocause Pharmaceutical Co Ltd
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
H
Hubei Biocause Pharmaceutical Co Ltd
SZSE:000627
Tax Provision
ÂĄ196.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
China Life Insurance Co Ltd
SSE:601628
Tax Provision
-ÂĄ18.3B
CAGR 3-Years
-59%
CAGR 5-Years
-82%
CAGR 10-Years
-12%
Ping An Insurance Group Co of China Ltd
SSE:601318
Tax Provision
-ÂĄ18B
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
-3%
New China Life Insurance Company Ltd
SSE:601336
Tax Provision
-ÂĄ256m
CAGR 3-Years
43%
CAGR 5-Years
N/A
CAGR 10-Years
14%
S
Sunshine Insurance Group Co Ltd
HKEX:6963
Tax Provision
-ÂĄ1.9B
CAGR 3-Years
-37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hubei Biocause Pharmaceutical Co Ltd
Glance View

Market Cap
21B CNY
Industry
Insurance

Hubei Biocause Pharmaceutical Co., Ltd. is an investment holding company that engages in the insurance industry. The company is headquartered in Jingmen, Hubei and currently employs 2,239 full-time employees. is a China-based company principally engaged in insurance business, such as life insurance, health insurance and casualty insurance. The firm is also involved in pharmaceutical business and chemical business. The Company’s products include polypropylene and Ibuprofen. The firm distributes its products in domestic market and to overseas markets, with Central China and South China as its main markets.

Intrinsic Value
4.46 CNY
Undervaluation 4%
Intrinsic Value
Price
H

See Also

What is Hubei Biocause Pharmaceutical Co Ltd's Tax Provision?
Tax Provision
196.7m CNY

Based on the financial report for Sep 30, 2024, Hubei Biocause Pharmaceutical Co Ltd's Tax Provision amounts to 196.7m CNY.

What is Hubei Biocause Pharmaceutical Co Ltd's Tax Provision growth rate?
Tax Provision CAGR 1Y
-64%

Over the last year, the Tax Provision growth was -64%.

Back to Top